OA03.03 Multi-Institutional Study of Pneumonitis After Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer

Sita, Timothy L.; Hassanzadeh, Comron; Savoor, Rohan; Samson, Pamela; Bradley, Jeffrey D.; Gentile, Maria Teresa; Roach, Michael C.; Mohindra, Nisha; Waqar, Saiama N.; Robinson, C.G.; Kruser, Tim J.

doi:10.1016/j.jtho.2019.09.034

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 The PFS in this study was also lower than that reported in retrospective analyses of unselected patients, which reached at least 14 months. [19][20][21] Although the median PFS with CRT and durvalumab was numerically higher than that with CRT alone, the Kaplan-Meier plot reveals that the survival curves are largely overlapping, indicating a lack of benefit with durvalumab. This finding is in accordance with previous assessments of anti-PD-(L)1 immunotherapy among patients with EGFR-mutated NSCLC, which have consistently revealed suboptimal outcomes.…”

Section: Discussionmentioning

confidence: 97%

“…28 In a separate analysis, all-grade nonpneumonitis irAEs occurred at similar frequencies in the EGFR-positive and EGFR-negative durvalumab subgroups (14% versus 15%). 29 However, small retrospective studies have revealed higher rates of toxicity with durvalumab overall, 19,21,30 suggesting outside of a selected clinical trial population, the risk of irAEs may be higher. Previous data have indicated that patients who experience high-grade irAEs may derive greater clinical benefit from immunotherapy [31][32][33] ; however, we did not observe this pattern in our cohort.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Aredo

Mambetsariev

Hellyer

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Aredo

Mambetsariev

Hellyer

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…However, 70% of these patients restarted durvalumab after the pneumonitis resolved, with a recurrence rate of 14%. The presence of pneumonitis did not affect survival outcomes[ 49 ].…”

Section: Description and Management Of Toxicity Associated With The Pmentioning

confidence: 99%

Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck

Mielgo-Rubio¹,

Rojo²,

Mezquita-Pérez³

et al. 2020

WJCO

View full text Add to dashboard Cite

After publication of the PACIFIC trial results, immune checkpoint inhibitor-based immunotherapy was included in the treatment algorithm of locally advanced non-small cell lung cancer (NSCLC). The PACIFIC trial demonstrated that 12 mo of durvalumab consolidation therapy after radical-intent platinum doublet chemotherapy with concomitant radiotherapy improved both progression-free survival and overall survival in patients with unresectable stage III NSCLC. This is the first treatment in decades to successfully improve survival in this clinical setting, with manageable toxicity and without deterioration in quality of life. The integration of durvalumab in the management of locally advanced NSCLC accentuates the need for multidisciplinary, coordinated decision-making among lung cancer specialists, bringing new challenges and controversies as well as important changes in clinical work routines. The aim of the present article is to review—from a practical, multidisciplinary perspective—the findings and implications of the PACIFIC trial. We evaluate the immunobiological basis of durvalumab as well as practical aspects related to programmed cell death ligand 1 determination. In addition, we comprehensively assess the efficacy and toxicity data from the PACIFIC trial and discuss the controversies and practical aspects of incorporating durvalumab into routine clinical practice. Finally, we discuss unresolved questions and future challenges. In short, the present document aims to provide clinicians with a practical guide for the application of the PACIFIC regimen in routine clinical practice.

show abstract

OA03.03 Multi-Institutional Study of Pneumonitis After Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer

Cited by 2 publications

References 0 publications

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck

Contact Info

Product

Resources

About